Biotech tries everything it can in Nash
The Nash pipeline is pharmacologically diverse, and some projects look like very long shots.
Evaluate Vantage 2023 Preview: free to download now
After a tough time for many in biopharma, what does 2023 hold for the sector? Find out in our preview of the year ahead.
Lilly and Pfizer fight for new territory in obesity and diabetes
Both developers lay out ambitious plans for oral projects to rival injected GLP-1s, while Lilly strives to build on Mounjaro.
The problem with Her2-low testing
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
Gossamer could put pressure on Merck
The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.
Abeona takes on Amryt – and more importantly, Krystal
Three new epidermolysis bullosa therapies are approaching the US, and expectations vary wildly.
Looking for winners in geographic atrophy
NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
Cancer “vaccines” enter the neoantigen stage
Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
PCSK9 pipeline shows signs of saturation
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
